In addition to the Phase IIb zoster study, valomaciclovir will also be studied in a separate Phase II clinical trial as a therapy in managing the most severe sequelae of a herpes-zoster infection, post-herpetic neuralgia.
In addition to the studies directed at herpes zoster, valomaciclovir is also being studied in a Phase II trial of acute infectious mononucleosis, a syndrome commonly seen in adolescents and young adults, caused by Epstein-Barr virus, also a member of the herpes virus family.
Brian Murphy, chief medical officer of Epiphany, said: “We look forward to examining the clinical utility of valomaciclovir in multiple conditions associated with herpes viruses and plan to maximize the broad-acting antiviral profile of this drug.”